It is now over 50 years since systemic agents were first used to treat malignant disease. Initial results were positive, with cytotoxic chemotherapy achieving success in haematological malignancies, but these successes have not been reproduced for the majority of adult solid tumours, principally because the approach does not target tumour cells sufficiently and exclusively. Copyright © 2006 John Wiley & Sons, Ltd.
Sorafenib is the first dual action oral multi-kinase inhibitor to target serine/threonine and receptor tyrosine kinases in both the tumour cell and the tumour vasculature. Phase II studies and now the largest ever phase III study in advanced renal cell cancer suggest that sorafenib will be a valuable new therapy for patients with kidney cancer. Copyright © 2006 John Wiley & Sons, Ltd.
Multiple Sclerosis (MS) is a multi-focal disease of the central nervous system (CNS) that is characterised by inflammation, demyelination and axonal degeneration. In the majority of MS patients, the disease presents with a relapsing remitting course at disease onset. Relapsing remitting MS (RRMS); affects around two thirds of the 85 000 people in the UK with MS.1 The aims of treatment in RRMS are not only to prevent the rate of relapse, but also to slow down patients' disability progression. Copyright © 2007 Wiley Interface Ltd
An overview of the clinical trial data presented at the International Diabetes Federation (IDF) Congress and the Diabetes UK Annual Professional Conference, highlighing some of the latest developments and approaches to tackling the growing global problem of diabetes. Copyright © 2007 Wiley Interface Ltd
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：